Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bicara Therapeutics Inc. - Common Stock
(NQ:
BCAX
)
25.64
+0.64 (+2.56%)
Official Closing Price
Updated: 4:15 PM EDT, Jun 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicara Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
↗
June 13, 2026
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara (BCAX) Q4 2025 Earnings Transcript
↗
June 01, 2026
Bicara (BCAX) Q4 2025 Earnings Transcript
Via
The Motley Fool
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
↗
May 22, 2026
Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the...
Via
MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates
↗
May 11, 2026
Via
Chartmill
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
May 21, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
↗
May 15, 2026
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
↗
May 15, 2026
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
↗
May 14, 2026
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development...
Via
MarketBeat
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara (BCAX) Q1 2026 Earnings Transcript
↗
May 11, 2026
Bicara (BCAX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Bicara Therapeutics Q1 Earnings Call Highlights
↗
May 11, 2026
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while...
Via
MarketBeat
Topics
Earnings
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 11, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
↗
May 04, 2026
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
May 04, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
↗
April 01, 2026
Via
Chartmill
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
↗
March 30, 2026
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.
↗
March 26, 2026
This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 23, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 04, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 26, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
February 24, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
February 24, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Participate in Upcoming Investor Conferences
February 23, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
February 19, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 05, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
January 12, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
December 15, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
December 06, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.